TrialBlood advances2025

Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.

Mark J Levis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.